



## **FOR IMMEDIATE RELEASE**

---

### **CONTACT INFORMATION:**

Lauren Whaley, Jennings, 919-929-0225, [lwhaley@jenningsco.com](mailto:lwhaley@jenningsco.com)

### **Entegriion lands prototype development contract with the Navy**

*Research Triangle Park, N.C., September 30, 2008* – Entegriion announced today that it has been awarded a contract from the Department of the Navy for the development of an integrated dried blood plasma storage and administration prototype. The single integrated unit will have two chambers, one for dried plasma powder and one for saline, a reconstitution fluid. Because of the difficulties in storing blood and blood products for long periods of time, this prototype would allow for lengthy shelf life and ease of administration.

The single unit will feature a breakable wall between the two chambers for rapid mixing. This reconstituted plasma would be administered intravenously to restore the normal blood clotting ability of a severely wounded patient. The prototype will be constructed of a unique flexible and durable plastic, to support the storage of dried plasma powder at extreme temperatures. The Department of the Navy contract requires that Entegriion complete this prototype within six months.

“Entegriion is honored by the Navy’s confidence in our experience toward improving the stability and availability of blood and blood components, wherever they are needed,” according to Stan Eskridge, Entegriion's president and CEO.

Resusix, concentrated human plasma that is spray dried for long-term storage, is currently in development at Entegriion. Clinical trials will begin in the late 2009 and spray dried plasma for civilian application is expected by 2012.

### **About Entegriion**

Entegriion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs for hemorrhage control, resuscitation and associated tissue repair. The company is based in North Carolina’s Research

Triangle Park, and is the inventor of Stasilon™ – the hemostatic medical textile technology cleared by the FDA for use by prescription and also by consumers – from which multiple hemorrhage control products are being made.

Building upon technologies licensed from the University of North Carolina, Entegriion's portfolio includes platelet-derived platform technologies that are being developed as topical gels and sprays for tissue repair, infusible hemostatic agents for the control of internal hemorrhage, and novel vehicles for delivery of drugs to targeted tumors and other sites of internal bleeding. Entegriion has also developed proprietary techniques for drying plasma and other blood components to provide for long shelf life with rapid rehydration for emergent and clinical use. For more information, visit [www.entegriion.com](http://www.entegriion.com).

###